Edition:
United States

Enanta Pharmaceuticals Inc (ENTA.OQ)

ENTA.OQ on NASDAQ Stock Exchange Global Select Market

27.97USD
23 Feb 2017
Change (% chg)

-- (--)
Prev Close
$27.97
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
86,020
52-wk High
$37.24
52-wk Low
$20.92

ENTA.OQ

Chart for ENTA.OQ

About

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets:... (more)

Overall

Beta: 0.67
Market Cap(Mil.): $532.58
Shares Outstanding(Mil.): 19.04
Dividend: --
Yield (%): --

Financials

  ENTA.OQ Industry Sector
P/E (TTM): -- 44.59 29.71
EPS (TTM): -0.50 -- --
ROI: -3.52 -3.18 12.94
ROE: -3.57 5.86 14.09

BRIEF-Enanta Pharmaceuticals Q1 loss per share $0.26

* Enanta Pharmaceuticals reports financial results for its fiscal first quarter ended december 31, 2016

Feb 08 2017

BRIEF-Enanta pharmaceuticals says EMA grants accelerated assessment for Abbvie's investigational HCV regimen of Glecaprevir/Pibrentasvir

* Says EMA grants accelerated assessment for Abbvie's investigational HCV Regimen Of Glecaprevir/Pibrentasvir

Jan 24 2017

BRIEF-Enanta reports high SVR12 rates achieved in Genotype 1 chronic HCV infected Japanese patients

* Enanta - in certain-1 study, 99 percent genotype 1 chronic hepatitis-C infected Japanese patients without cirrhosis got svr 12 with 8 weeks of G/P treatment

Jan 09 2017

BRIEF-Enanta Pharmaceuticals reports the appointment of Lesley Russell to its board of directors

* Enanta Pharmaceuticals announces the appointment of Dr. Lesley Russell to its board of directors Source text for Eikon: Further company coverage:

Nov 22 2016

BRIEF-Enanta Pharmaceuticals announces AbbVie's investigational HCV regimen receives U.S. FDA breakthrough therapy designation

* Enanta Pharmaceuticals announces AbbVie's investigational HCV regimen receives U.S. FDA breakthrough therapy designation

Sep 30 2016

BRIEF-Enanta Pharmaceuticals to present data on RSV inhibitor at annual RSV conference

* Presents data on a novel non-fusion inhibitor of Respiratory Syncytial Virus (RSV) at the 10th annual respiratory syncytial virus conference

Sep 29 2016

BRIEF-Enanta Pharmaceuticals initiates phase 1 clinical study of EDP-305

* Initiates phase 1 clinical study of Edp 305, its lead FXR agonist for the treatment of non-alcoholic Steatohepatitis (NASH)

Sep 28 2016

More From Around the Web

Earnings vs. Estimates